Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

251 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Human tumor cell lysates as a protein source for the detection of cancer antigen-specific humoral immunity.
Goodell V, Disis ML. Goodell V, et al. Among authors: disis ml. J Immunol Methods. 2005 Apr;299(1-2):129-38. doi: 10.1016/j.jim.2005.02.002. Epub 2005 Mar 18. J Immunol Methods. 2005. PMID: 15914197
Adoptive T-cell therapy for the treatment of solid tumours.
Knutson KL, Almand B, Mankoff DA, Schiffman K, Disis ML. Knutson KL, et al. Among authors: disis ml. Expert Opin Biol Ther. 2002 Jan;2(1):55-66. doi: 10.1517/14712598.2.1.55. Expert Opin Biol Ther. 2002. PMID: 11772340 Review.
Flt3 ligand as a vaccine adjuvant in association with HER-2/neu peptide-based vaccines in patients with HER-2/neu-overexpressing cancers.
Disis ML, Rinn K, Knutson KL, Davis D, Caron D, dela Rosa C, Schiffman K. Disis ML, et al. Blood. 2002 Apr 15;99(8):2845-50. doi: 10.1182/blood.v99.8.2845. Blood. 2002. PMID: 11929774 Clinical Trial.
Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide, p369-377, results in short-lived peptide-specific immunity.
Knutson KL, Schiffman K, Cheever MA, Disis ML. Knutson KL, et al. Among authors: disis ml. Clin Cancer Res. 2002 May;8(5):1014-8. Clin Cancer Res. 2002. PMID: 12006513 Clinical Trial.
Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines.
Disis ML, Gooley TA, Rinn K, Davis D, Piepkorn M, Cheever MA, Knutson KL, Schiffman K. Disis ML, et al. J Clin Oncol. 2002 Jun 1;20(11):2624-32. doi: 10.1200/JCO.2002.06.171. J Clin Oncol. 2002. PMID: 12039923 Clinical Trial.
Clonal diversity of the T-cell population responding to a dominant HLA-A2 epitope of HER-2/neu after active immunization in an ovarian cancer patient.
Knutson KL, Disis ML. Knutson KL, et al. Among authors: disis ml. Hum Immunol. 2002 Jul;63(7):547-57. doi: 10.1016/s0198-8859(02)00401-9. Hum Immunol. 2002. PMID: 12072190
Delayed type hypersensitivity response to recall antigens does not accurately reflect immune competence in advanced stage breast cancer patients.
Schiffman K, Rinn K, Disis ML. Schiffman K, et al. Among authors: disis ml. Breast Cancer Res Treat. 2002 Jul;74(1):17-23. doi: 10.1023/a:1016009317796. Breast Cancer Res Treat. 2002. PMID: 12150448
Identification of tumor-specific antibodies in patients with breast cancer vaccinated with gene-modified allogeneic tumor cells.
Dols A, Meijer SL, Hu HM, Goodell V, Disis ML, Von Mensdorff-Pouilly S, Verheijen R, Alvord WG, Smith JW 2nd, Urba WJ, Fox BA. Dols A, et al. Among authors: disis ml. J Immunother. 2003 Mar-Apr;26(2):163-70. doi: 10.1097/00002371-200303000-00009. J Immunother. 2003. PMID: 12616108 Clinical Trial.
Immunotherapy for breast cancer.
Knutson KL, Bishop MR, Schiffman K, Disis ML. Knutson KL, et al. Among authors: disis ml. Cancer Chemother Biol Response Modif. 2002;20:351-69. Cancer Chemother Biol Response Modif. 2002. PMID: 12703214 Review. No abstract available.
Soluble cytokines can act as effective adjuvants in plasmid DNA vaccines targeting self tumor antigens.
Disis ML, Shiota FM, McNeel DG, Knutson KL. Disis ML, et al. Immunobiology. 2003;207(3):179-86. doi: 10.1078/0171-2985-00230. Immunobiology. 2003. PMID: 12777059
251 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback